 |
Hikma H1 revenue grows 10pc to $1.427bn, sees rosy outlookHikma Pharmaceuticals’ first-half (H1) revenue grew 10% to $1.569 billion compared to $1.427 billion in H1 2023) with all its three business segments performing well. Hikma now expects Group full year revenue growth of 6% to 8%, up from More… |
|
Hikma H1 revenue grows 10pc to $1.427bn, sees rosy outlookHikma Pharmaceuticals’ first-half (H1) revenue grew 10% to $1.569 billion compared to $1.427 billion in H1 2023) with all its three business segments performing well. Hikma now expects Group full year revenue growth of 6% to 8%, up from More… |
 |
Hikma 2023 revenue grows 14pc to $2.88bn; sees robust 2024Hikma Pharmaceuticals has posted revenue growth of 14% (15% in constant currency) to $2.88 billion in 2023 compared to $2.52 billion in 2022. In 2023, it continued to deliver on its purpose of making high More… |
 |
Hikma to bring Guardant Health cancer diagnostic to MENAHikma Pharmaceuticals, a multinational pharmaceutical company, has announced an exclusive agreement with Guardant Health, a leading precision oncology company. Through the agreement, Hikma has the exclusi More… |
 |
Hikma signs licensing deal to bring Oregovomab to MENAHikma Pharmaceuticals, a multinational pharmaceutical company, announced an exclusive license agreement with CanariaBio, a Korean biopharmaceutical company focused on the development and commercialisation of immunotherapies for cancer. More… |
 |
Hikma, SK Biopharma ink strategic partnership for Mena marketHikma Pharmaceuticals (Hikma), a multinational pharmaceutical company based in Jordan, has sealed a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of More… |
|
Hikma, SK Biopharma ink strategic partnership for Mena marketHikma Pharmaceuticals (Hikma), a multinational pharmaceutical company based in Jordan, has sealed a new strategic partnership and exclusive licensing agreement with SK Biopharmaceuticals, a global biotech company focused on the development of More… |
 |
Hikma and Rakuten Medical sign exclusive licensing dealHikma Pharmaceuticals has signed an exclusive licensing and commercialisation deal with Rakuten Medical, to commercialise products in Rakuten’s pipeline using its photoimmunotherapy technology platform, Alluminox, in all its Mena markets More… |
 |
Hikma H1 revenues rise 18pc to $1.43bn, sees Generics growthHikma Pharmaceuticals, the multinational pharmaceutical firm, has seen its first-half (H1) core group revenue grow 18% to $1.43 billion compared to $1.21 billion in H1 2022, driven by a strong performance in all its three businesses. More… |
|
Hikma H1 revenues rise 18pc to $1.43bn, sees Generics growthHikma Pharmaceuticals, the multinational pharmaceutical firm, has seen its first-half (H1) core group revenue grow 18% to $1.43 billion compared to $1.21 billion in H1 2022, driven by a strong performance in all its three businesses. More… |
